tiprankstipranks
Fresenius Medical Care AG & Co. KGaA (GB:0H9X)
LSE:0H9X
Holding GB:0H9X?
Track your performance easily

Fresenius Medical Care AG & Co. KGaA (0H9X) Share Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

0H9X Analyst Ratings

Hold
16Ratings
3 Buy
9 Hold
4 Sell
Based on 16 analysts giving stock ratings to
Fresenius
Medical Care AG & Co. KGaA
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0H9X Stock 12 Month Forecast

Average Price Target

€44.27
▲(1.57% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Fresenius Medical Care AG & Co. KGaA in the last 3 months. The average price target is €44.27 with a high forecast of €78.00 and a low forecast of €34.00. The average price target represents a 1.57% change from the last price of €43.59.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"€32","79":"€79","43.75":"€43.8","55.5":"€55.5","67.25":"€67.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€44.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,43.75,55.5,67.25,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.52,46.1723076923077,48.824615384615385,51.47692307692308,54.12923076923077,56.78153846153846,59.433846153846154,62.08615384615385,64.73846153846154,67.39076923076922,70.04307692307692,72.69538461538461,75.34769230769231,{"y":78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.52,43.57769230769231,43.635384615384616,43.69307692307692,43.75076923076924,43.80846153846154,43.86615384615385,43.923846153846156,43.98153846153846,44.03923076923077,44.09692307692308,44.15461538461539,44.2123076923077,{"y":44.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.52,42.78769230769231,42.05538461538462,41.323076923076925,40.59076923076923,39.85846153846154,39.12615384615385,38.393846153846155,37.66153846153846,36.92923076923077,36.19692307692308,35.464615384615385,34.73230769230769,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36.3,"date":1704412800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34.8,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34.52,"date":1709251200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":33.6,"date":1712275200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":38.23,"date":1714694400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":39.71,"date":1717718400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":36.22,"date":1720137600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34.56,"date":1722556800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":35.65,"date":1725580800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":37.7,"date":1728000000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":35.96,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.99,"date":1733443200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":43.52,"date":1735862400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€78.00Average Price Target€44.27Lowest Price Target€34.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
€39
Hold
-10.52%
Downside
Reiterated
11/26/24
UBS Remains a Hold on Fresenius Medical Care AG & Co. KGaA (0H9X)
Barclays
€39€41
Hold
-5.93%
Downside
Reiterated
11/21/24
Fresenius Medical Care AG #x26; Co KGaA (FME:GR) (FMS) PT Raised to EUR41 at BarclaysBarclays analyst Hassan Al-Wakeel raised the price target on Fresenius Medical Care AG Co KGaA (FME:GR) (NYSE: FMS) to EUR41.00 (from EUR39.00) while maintaining a Equalweight rating.
Deutsche Bank
€34
Hold
-21.99%
Downside
Reiterated
11/06/24
Deutsche Bank Keeps Their Hold Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)
Citi
€40€41
Hold
-5.93%
Downside
Reiterated
10/23/24
Fresenius Medical Care AG #x26; Co KGaA (FME:GR) (FMS) PT Raised to EUR41 at CitiCiti analyst Veronika Dubajova raised the price target on Fresenius Medical Care AG Co KGaA (FME:GR) (NYSE: FMS) to EUR41.00 (from EUR40.00) while maintaining a Neutral rating.
DZ BANK AG
Hold
Reiterated
12/27/24

Best Analysts Covering Fresenius Medical Care AG & Co. KGaA

Which Analyst Should I Follow If I Want to Buy GB:0H9X and Sell After:
1 Month
xxx
Success Rate
23/50 ratings generated profit
46%
Average Return
-1.65%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.00% of your transactions generating a profit, with an average return of -1.65% per trade.
3 Months
xxx
Success Rate
22/50 ratings generated profit
44%
Average Return
+0.18%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.00% of your transactions generating a profit, with an average return of +0.18% per trade.
1 Year
James VaneJefferies
Success Rate
18/38 ratings generated profit
47%
Average Return
-3.65%
reiterated a sell rating last month
Copying James Vane's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of -3.65% per trade.
2 Years
xxx
Success Rate
15/38 ratings generated profit
39%
Average Return
-8.11%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 39.47% of your transactions generating a profit, with an average return of -8.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0H9X Analyst Recommendation Trends

Rating
Sep 24
Oct 24
Nov 24
Dec 24
Jan 25
Strong Buy
0
0
0
0
0
Buy
5
2
5
7
6
Hold
7
2
12
17
15
Sell
11
12
13
13
7
Strong Sell
0
0
0
0
0
total
23
16
30
37
28
In the current month, 0H9X has received 6 Buy Ratings, 15 Hold Ratings, and 7 Sell Ratings. 0H9X average Analyst price target in the past 3 months is €44.27.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0H9X Financial Forecast

0H9X Earnings Forecast

Next quarter’s earnings estimate for 0H9X is €0.92 with a range of €0.72 to €1.64. The previous quarter’s EPS was €0.82. 0H9X beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.82% of the time in the same period. In the last calendar year 0H9X has Outperformed its overall industry.
Next quarter’s earnings estimate for 0H9X is €0.92 with a range of €0.72 to €1.64. The previous quarter’s EPS was €0.82. 0H9X beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.82% of the time in the same period. In the last calendar year 0H9X has Outperformed its overall industry.

0H9X Sales Forecast

Next quarter’s sales forecast for 0H9X is €5.50B with a range of €3.84B to €9.82B. The previous quarter’s sales results were €4.76B. 0H9X beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 41.10% of the time in the same period. In the last calendar year 0H9X has Outperformed its overall industry.
Next quarter’s sales forecast for 0H9X is €5.50B with a range of €3.84B to €9.82B. The previous quarter’s sales results were €4.76B. 0H9X beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 41.10% of the time in the same period. In the last calendar year 0H9X has Outperformed its overall industry.

0H9X Stock Forecast FAQ

What is GB:0H9X’s average 12-month price target, according to analysts?
Based on analyst ratings, Fresenius Medical Care AG & Co. KGaA’s 12-month average price target is €44.27.
    What is GB:0H9X’s upside potential, based on the analysts’ average price target?
    Fresenius Medical Care AG & Co. KGaA has 1.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Fresenius Medical Care AG & Co. KGaA a Buy, Sell or Hold?
          Fresenius Medical Care AG & Co. KGaA has a consensus rating of Hold, which is based on 3 buy ratings, 9 hold ratings and 4 sell ratings.
            What is Fresenius Medical Care AG & Co. KGaA’s share price target?
            The average share price target for Fresenius Medical Care AG & Co. KGaA is €44.27. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €78.00 ,and the lowest forecast is €34.00. The average share price target represents 1.57% Increase from the current price of €43.586.
              What do analysts say about Fresenius Medical Care AG & Co. KGaA?
              Fresenius Medical Care AG & Co. KGaA’s analyst rating consensus is a Hold. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of Fresenius Medical Care AG & Co. KGaA?
                To buy shares of GB:0H9X, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis